Q-omics provides the consensus-scored KCTD14 profile across patient tissues and cancer cell-line models. KCTD14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD14 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, KCTD14 RNA expression shows 18,008 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where KCTD14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD14 survival associations across molecular data types. KCTD14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD14 RNA expression–survival associations across cancer types. High KCTD14 expression shows unfavorable associations in PAAD, LGG, KICH and LIHC, but favorable associations in KIRC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD14 RNA expression.
This table summarizes KCTD14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD14 shows lower tumor expression in LUSC, KICH, BRCA and PRAD and higher tumor expression in COAD and READ. The COAD box plot shows higher KCTD14 RNA expression in tumor versus normal tissue (log2 FC = +1.616, t-test p < 0.001).
This table shows molecular features associated with KCTD14 in patient tissues and cancer cell lines. In patient samples, KCTD14 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
